The short answer
Setmelanotide is a melanocortin-4 receptor agonist approved for rare genetic obesity caused by defects in the MC4R pathway. It works through an entirely different mechanism from the incretins, and its VENTURE Phase 3 trial extended use to children aged 2 to 5.
Key facts
- Target
- Melanocortin-4 receptor (MC4R)
- Not
- A GLP-1 or incretin agonist
- Indication
- Rare MC4R pathway-associated obesity
- VENTURE trial
- Phase 3, ages 2-5, 1 year, open-label
- Published
- Lancet Diabetes Endocrinol 2025 (PMID 39549719)
- Related receptor family
- MC1R to MC5R
A different pathway entirely
The incretin drugs act on GLP-1, GIP and glucagon receptors. Setmelanotide acts on the melanocortin-4 receptor, part of a five-member family whose members sit in different tissues: MC1R on melanocytes driving pigmentation, MC2R in the adrenal cortex, MC3R and MC4R centrally in energy balance.
Why MC4R is a genuine obesity target
The melanocortin pathway is a central regulator of energy balance, and defects in it cause severe early-onset obesity. That is not a hypothesis. It is a defined genetic mechanism with identified patients, which is why an agonist for it could be developed for a specific indication rather than for obesity in general.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What VENTURE reported
Argente and colleagues published a one-year, open-label, multicentre Phase 3 trial of setmelanotide in patients aged 2 to 5 with rare MC4R pathway-associated obesity in the Lancet Diabetes and Endocrinology in January 2025. Extending an approved medicine into very young children with a defined genetic condition is a narrow and specific development step.
Why it is not a competitor to the incretins
Different populations entirely. Setmelanotide addresses rare monogenic obesity in identified patients; the incretins address common polygenic obesity in very large populations. They are both obesity medicines in the way that two drugs for different cancers are both oncology medicines: the category is shared and little else is.
The melanocortin connection elsewhere in this catalogue
MC4R belongs to the same receptor family this site describes in its MT-2 articles. Alpha-MSH and its derivatives act across that family, and selectivity between members is the central design problem. Setmelanotide is what a deliberately selective, regulator-assessed melanocortin agonist looks like, which is a useful contrast with compounds described as non-selective.
Regulatory position and what is not implied
Setmelanotide is a licensed medicine for a specific rare indication, prescribed and monitored clinically. Nothing supplied as research material is related to it, and no melanocortin research compound is an alternative to it or covered by its approval.
Frequently asked questions
Is setmelanotide a GLP-1 drug?
No. It targets the melanocortin-4 receptor, an entirely different mechanism from the incretins.
Who is it for?
Patients with rare genetic obesity caused by defects in the MC4R pathway, a defined and narrow population.
What did VENTURE show?
It was a one-year open-label Phase 3 trial extending setmelanotide use to children aged 2 to 5 with MC4R pathway-associated obesity.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedArgente J et al., Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE). Lancet Diabetes Endocrinol 2025 (PMID 39549719)pubmed.ncbi.nlm.nih.gov
- PubMedTrapp CM et al., Setmelanotide in pediatric patients with rare forms of obesity. Curr Opin Endocrinol Diabetes Obes 2023 (PMID 36722447)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · alpha-MSH (CID 16133793)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Survodutide Comparison, Read ProperlyAn open-label semaglutide arm in a type 2 diabetes dose-finding trial. Why that is weaker evidence than a head-to-head, and what the numbers mean.
- Failing to Show Non-Inferiority Is Not Showing InferiorityREDEFINE 4 missed its non-inferiority endpoint. That is a specific statistical statement, and it is not the same as the drug being worse.
- Satiety and Nausea Run Through Different CircuitsA 2024 Nature paper showed hindbrain GLP-1 receptor circuits for satiety and aversion are dissociable. Nausea may not be the price of appetite suppression.
- Three Head-to-Heads, One Common ComparatorSURMOUNT-5, REDEFINE 4 and TRIUMPH-5 all use tirzepatide. What it means when one compound becomes the field's reference point.
- What Open-Label Does to a Weight-Loss TrialREDEFINE 4's registry record lists masking as none. Why an unblinded weight trial is weaker evidence, and where the effect creeps in.